Treatment options for visceral leishmaniasis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 2, 2006, Pages 187-197

  den Boer, Margriet ^a   Davidson, Robert N ^b,c  

^a Campaign for Access to Essential Medicines   (Switzerland)

^b MSF   (Netherlands)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

AmBisome; Amphotericin B; Liposomal amphotericin B (L AMB); Miltefosine; Paromomycin; Pentavolent antimonials; Sitamaquine; Sodium stibogluconate (SSG); Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOMUL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; ITRACONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMORBIDITY; DEATH; DRUG COST; DRUG HALF LIFE; HEADACHE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; MEDICAL DECISION MAKING; NEPHRITIS; RELAPSE; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL;

EID: 33646189629     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.2.187     Document Type: Review

References (98)

1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin. Dermatol. 14, 417-423 (1996).
2. Murray HW. Kala-azar - progress against a neglected disease. N. Engl. J. Med. 347, 1792-1794 (2002).
3. Herwaldt BL. Leishmaniasis. Lancet 354, 1109-1199 (1999).
4. Desjeux P. The increase in risk factors for Leishmania world wide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-143 (2001).
5. WHO. The world health report 2004. WHO, Geneva, Switzerland (2004).
6. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27, 305-318 (2004).
7. WHO. The world health report 2001. WHO, Geneva, Switzerland (2001).
8. WHO. The world health report 2003. WHO, Geneva, Switzerland (2003).
9. Ashford RW, Thomson MC. Visceral leishmaniasis in Sudan. A delayed development disaster? Ann. Trop. Med. Parasitol. 85(5), 571-572 (1991).
10. Marlet MV, Sang DK, Ritmeijer K, Muga RO, Onsongo J, Davidson RN. Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, northeastern Kenya, and south-eastern Ethiopia in 2000-01. Trans. R. Soc. Trop. Med. Hyg. 97(5), 515-518 (2003).
11. Sundar S, Rai M. The treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 6(16), 2821-2829 (2005).
12. Ritmeijer K, Davidson RN. Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989-2003. Royal Society of Tropical Medicine and Hygiene Joint Meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003. Field research in humanitarian medical programmes. Trans. R. Soc. Trop. Med. Hyg. 97, 609-613 (2003).
13. Badaró R, Jones T, Carvalho E et al. New perspectives on a subclinical form of visceral leishmaniasis. J. Infect. Dis. 154, 1003-1011 (1986).
14. Gama ME, Costa JM, Gomes CM, Corbett CE. Subclinical form of the American visceral leishmaniasis. Mem. Inst. Oswaldo Cruz 99(8), 889-893 (2004).
15. Zijlstra EE, El-Hassan AM. Leishmaniasis in Sudan. Visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 95, S27-S58 (2001).
16. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol. 97, S3-S15 (2003).
17. Seaman J, Mercer AJ, Sondorp E, Herwaldt BL. Epidemic visceral leishmaniasis in Southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann. Intern. Med. 124(7), 664-672 (1996).
18. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in Western Upper Nile, Southern Sudan: course and impact from 1984 to 1994. Int. J. Epidemiol. 24(4), 862-871 (1996).
19. Kumar R, Kumar P. Chowdhary RK et al. Kala-azar epidemic in Varanasi district, India. Bull. World Health Organ. 77(5), 371-374 (1999).
20. Murray H. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev. Anti Infect. Ther. 2(2), 279-292 (2004).
21. Sundar S, Murray H. Availability of miltefosine for the treatment of kala-azar in India. Bull. World Health Organ. 83(5), 394-395 (2005).
22. Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh and prospects for improved control. IJMR (2006) (In press).
23. Directorate General for Health Services 2005. National Kala Azar Surveillance Data, Dhaka, Bangladesh: government of Bangladesh (2005).
24. Ahluwalia IB, Bern C, Costa C et al. Leishmaniasis: consequences of a neglected disease in a community. Am. J. Trop. Hyg. 69(99), 624-628 (2003).
25. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg. 95, 1-5 (2001).
26. Davidson RN. AIDS and leishmaniasis. Genitourin. Med. 73, 237-239 (1997).
27. Bogdan C, Rollinghoff M. The immune response to Leishmania: mechanisms of parasite control and evasion. Int. J. Parasitol. 28, 121-134 (1998).
28. Faraut-Gambarelli F, Piarroux R, Deniau M et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41, 827-830 (1997).
29. Villanueva JL, Alarcon A, Bernabeu-Wittel M et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 19, 798-801 (2000).
30. Berenguer J, Cosin J, Miralles P, Lopez JC, Padilla B. Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 14, 2946-2948 (2000).
31. Desjeux P. Urbanization: an increasing risk factor for leishmaniasis. Wkly Epidemiol. Rec. 77, 44 (2002).
32. Lopez-Velez R, Casado JL, Pintado V. Decline of a visceral leishmaniasis epidemic in HIV-inflected patients after the introduction of highly active antiretroviral therapy (HAART). Clin. Microbiol. Infect. 7, 394-395 (2001).
33. Lyons L, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health 8(8), 733-739 (2003).
34. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3, 87-98 (2003).
35. Thakur CP, Narain S, Kumar N, Hassan SM, Jha DK, Kumar A. Amphotericin B is superior to sodium stibogluconate in the treatment of Indian post-kala-azar dermal leishmaniasis. Ann. Trop. Med. Parasitol. 92, 611-616 (1997).
36. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala azar dermal leishmaniasis. Ind. J. Med. Res. 91, 144-148 (1990).
37. Addy M, Nandy A. Ten years of kala-azar in west Bengal, Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. World Health Organ. 70, 341-346 (1992).
38. Goodwin LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg. 89, 339-341 (1995).
39. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 6, 849-854 (2001).
40. Rijal S, Chappuis F, Singh R et al. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans. R. Soc. Trop. Med. Hyg. 97, 350-354 (2003).
41. Gradoni L, Gramiccia M, Scalone A. Visceral leishmaniasis treatment, Italy. Emerg. Infect. Dis. 9, 1617-1620 (2003).
42. Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J. Parasitol. 70(2), 220-225 (1984).
43. Sundar S, Sinha PR, Agrawal NK et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg. 59, 139-143 (1998).
44. Deps PD, Viana MC, Falqueto A, Dietze R. Comparative study between sodium stibogluconate BP88 (Shandong Xinhua - China) and meglumine antimoniate (Rhodia - Brazil) on the treatment of cutaneous leishmaniasis, in the endemic area Corte de Pedra, Bahia, Brazil. Rev. Soc. Bras. Med. Trop. 33, 535-543 (2000).
45. Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans. R. Soc. Trop. Med. Hyg. 97(5), 597-598 (2003).
46. Moore E, O'Flaherty D, Heuvelmans H et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. 79(5), 388-393 (2001).
47. Veeken H, Ritmeijer K, Seaman J, Davidson RN. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health 5, 312-317 (2000).
48. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46(3), 296-306 (1992).
49. MSF Holland Northern Bangladesh assessment 17-27 October 2005 (internal report). (2005).
50. Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31, 1104-1106 (2000).
51. Collin S, Davidson R, Ritmeijer K et al. Conflict and kala-azar: determination of adverse outcomes of kala azar among patients in Southern Sudan. Clin. Infect. Dis. 38, 612-619 (2004).
52. Kanyok TP, Reddy MV, Chinnaswamy J, Danziger LH, Gangadharam PR. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob. Agents Chemother. 38(2), 170-173 (1994).
53. Kellina OI. Test-trials of the chemotherapeutic monomycin activity in experimental cutaneous leishmaniasis in albino mice (Russian; English abstract). Med. Parazitol. (Mosk.) 32, 572 (1963).
54. Neal RA. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann. Trop. Med. Parasitol. 62, 54-62 (1968).
55. El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother. 26, 745-751 (1984).
56. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg. 88(3), 334-339 (1994).
57. Neal RA, Allen S, McCoy N, Olliaro P, Croft SL. The sensitivity of Leishmania species to aminosidine. J. Antimicrob. Chemother. 35, 577-584 (1995).
58. Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res. 81, 421-425 (1995).
59. Callahan HL, Portal AC, Devereaux R, Grogl M. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41, 818-822 (1997).
60. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. 84(2), 221-225 (1990).
61. Thakur CP, Kanyok TP, Pandey AK et al. A prospective randomized, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone. Trans. R. Soc. Trop. Med. Hyg. 94(4), 429-431 (2000).
62. Thakur CP, Olliaro P, Gothoskar S et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin) - antimonial combinations, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg. 86(6), 615-616 (1992).
63. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomised dose-finding clinical trial. Trans. R. Soc. Trop. Med. Hyg. 89(2), 219-223 (1995).
64. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168(3), 715-720 (1993).
65. Paromomycin/SSG Evaluation South Sudan-statistical analysis. Koert Ritmeijer, MSF Holland.
66. Sinha PK, Bhattacharya SK, Thakur CP, Jha TK, Sundar S. Paromomycin as a new cure for visceral leishmaniasis in pediatric patients: preliminary analysis of a Phase III randomized controlled clinical trial. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10-15 (2005).
67. Jha TK, Sundar S, Bhattacharya SK, Sinha PK, Thakur CP. Paromomcyin as a new cure for visceral leishmaniasis: preliminary results of a Phase III randomized controlled trial of efficacy and safety. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10-15 (2005).
68. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SI, Desjeux F. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet 2, 34-41 (2002).
69. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop. Med. Int. Health 6, 928-934 (2001).
70. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr. Opin. Infect. Dis. 15, 593-598 (2002).
71. Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 6, 2821-2829 (2005).
72. Davidson RN, di Martino L, Gradoni L et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22, 938-943 (1996).
73. Berman JD, Badaro, R, Thakur CP et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76, 25-32 (1998).
74. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am. J. Trop. Med. Hyg. 66, 143-146 (2002).
75. Mueller M, Ritmeijer K, Balasegaram M, Koummuki M, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala azar. Tans. R. Soc. Trop. Med. Hyg. (2006) (In press).
76. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin. Infect. Dis. 38, 377-383 (2004).
77. Thakur CP, Jha TK. Efficacy and safety of three different regimens of intravenous amphotericin B emulsion for treatment naïve and treatment resistant cases of kala azar. Clinical study report. (2003).
78. Seaman J, Boer C, Wilkinson R, de Jong J, de Wilde E, Sondorp E. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21, 188-193 (1995).
79. Liposomal amphotericin B in visceral leishmaniasis treatment. Proceedings of a WHO/TDR consultation, April 2005. Clin. Infect. Dis. (2006) (In press).
80. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 323, 419-422 (2001).
81. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37, 800-804 (2003).
82. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40, 1214-1218 (1996).
83. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38, 1041-1047 (1996).
84. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347(22), 1739-1746 (2002).
85. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352(9143), 1821-1823 (1998).
86. Bhattacharya SK, Jha TK, Sundar S et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. 38, 217-221 (2004).
87. Perez-Victoria FJ, Sanchez-Canete M, Castanys S, Gamarro F. Experimental miltefosine resistance: Leishmania sensitivity to miltefosine depends on drug uptake mechanism. Presented at the 3rd International Congress on Leishmaniasis. Palermo, Sicily, Italy, April 10-15 (2005).
88. Olliari P, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen J, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet 5, 763-774 (2005).
89. Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for leishmaniasis in immunocompromosed patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. 39, 1520-1523 (2004).
90. Neal RA, Croft SL, Nelson DJ. Anti-leishmanial effect of allopurinol ribonucleoside and the related compounds, allopurinol, thiopurinol, thiopurinol ribonucleoside, and of formycin B, sinefungin and the lepidine WR6026. Trans. R. Soc. Trop. Med. Hyg. 79, 122-128 (1985).
91. Jha TK, Sundar S, Thakur CP, Felton JM, Sabin AJ, Horton J. A Phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 73, 1005-1011 (2005).
92. Wasunna MK, Rashid JR, Mbui J et al. A Phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73, 871-876 (2005).
93. Berman J. Clinical status of agents being developed for leishmaniasis. Expert Opin. Investig. Drugs 14, 337-346 (2005).
94. Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen kala-azar deaths in south Sudan (1999-2002). Trop. Med. Intl Health 11, 509-512 (2006).
95. Goswami RP, Bairagi B, Kundu PK. K39 strip test-easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India. J. Assoc. Physicians India 51, 759-761 (2003).
96. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366, 1561-1577 (2005).
97. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol. 97, S29-S45 (2003).
98. Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50, 73-79 (2006).